To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
- 
      
    Sponsored Tools Program
Learn more about how MJFF can help share your tools.
 - 
      
    Tools Consortium
MJFF is working with industry to develop priority tools.
 - 
      
    Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
 
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
          Filters
        
        
      
      
  EEA1 Edited Endo-IP iPSC Line
    
                    
  
    Human iPS Cell
                
  KOLF2.1J human iPSC line with DOX-NGN2 + HA-tagged EEA1 for Endo-IP.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative. Estimated Availability: late 2026
              
      
      
  TMEM192 Edited Lyso-IP iPSC Line
    
                    
  
    Human iPS Cell
                
  KOLF2.1J human iPSC line with DOX-NGN2 + HA-tagged TMEM192 for Lyso-IP.These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD). Cell line development is also supported by MJFF Targets to Therapies (T2T) Initiative. Estimated Availability: late 2026
              
      
      
  Human O-GlcNAc T72 aSyn ELISA
    
                    
  
    Assay
                
  ELISA kit for quantification of alpha-synuclein with O-GlcNAc on Threonine72 (O-GlcNAc T72 aSyn).This assay development project is part of the MJFF Targets to Therapies (T2T) Initiative. Estimated availability: Late 2027
              
      
      
  Human pS106 Rab12 ELISA
    
                    
  
    Assay
                
  ELISA kit for quantification of Rab12 phosphorylated at Serine106 (pS106 Rab12).Estimated availability: Late 2026
              
      
      
  Human pS111 Rab13 ELISA
    
                    
  
    Assay
                
  ELISA kit for quantification of Rab13 phosphorylated at Serine111 (pS111 Rab13)Estimated availability: Late 2027
              
      
      
  Human Rab13 ELISA
    
                    
  
    Assay
                
  ELISA kit for quantification of Rab13.Estimated availability: Late 2027
              
      
      
  Alpha-Synuclein Aggregation Assay in Immortalized Neurons
    
                    
  
    Assay
                
  High-throughput in vitro assay to detect alpha-synuclein aggregation developed in a dopamine neuron-like cell line of human origin. Available as a fee-for-service assay. 
Generated as part of the Industry Tools Consortium.
              
      
      
  Alpha-Synuclein Aggregation Assay in iPSC-derived Triculture
    
                    
  
    Assay
                
  High-throughput in vitro assay to detect alpha-synuclein aggregation in iPSC-derived neuron and glial tri-culture system treated with alpha-synuclein pre-formed fibrils. Available as a fee-for-service assay. Estimated Availability: Late 2027
              
      
      
  TMEM175 Edited iPSC Lines
    
                    
  
    Human iPS Cell
                
  KOLF2.1J human iPSC line with CRISPR-engineered mutations in TMEM175, including - -Q65P (heterozygous and homozygous) - in development, est late 2025
 - -M393T (heterozygous and homozygous)
 - -DOX-NGN2 + TMEM192-HA + Knockout (heterozygous and homozygous) - in development, est late 2026
 
      
  GBA1 Edited iPSC Lines
    
                    
  
    Human iPS Cell
                
  KOLF2.1J human iPSC line with CRISPR-engineered mutations in GBA1, including:- -K198E (heterozygous and homozygous)
 - -E326K (heterozygous and homozygous)
 - -T369M (heterozygous and homozygous)
 - -N370S (heterozygous and homozygous)
 - -L444P (heterozygous and homozygous) - in development, est late 2025
 - -D448H (heterozygous and homozygous) - in development, est late 2025
 - -D448V (heterozygous and homozygous)
 - -Noncoding rs3115534 (heterozygous and homozygous) - in development, est late 2025
 - -DOX-NGN2 + TMEM192-HA + L444P (heterozygous and homozygous) - in development, est late 2026
 
      
    Have questions or need additional information?
    
        
  Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
      
    "We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
    
        
      
  Heather Melrose, PhD
      
  Mayo Clinic